Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 3/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 3/20 | 0.37 |
| ▸ | CDK8 | P49336 | 3/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | CDK7 | P50613 | 2/20 | 0.37 |
| ▸ | CDK9 | P50750 | 2/20 | 0.37 |
| ▸ | CCNH | P51946 | 2/20 | 0.37 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22164595 | 0.86 | HTT (0.41) | HTTLMNASMN1; SMN2CASP3DHODH | |
| SCHEMBL26114227 | 0.84 | CASP3 (0.39) | HTTLMNASMN1; SMN2CASP3CYP1A2 | |
| SCHEMBL19836555 | 0.81 | NPC1 (0.38) | LMNASMN1; SMN2CYP2C9CYP2C19CCNC | |
| SCHEMBL18081416 | 0.81 | LMNA (0.37) | HTTLMNACYP1A2CCNCCDK8 | |
| SCHEMBL25082278 | 0.80 | CDK9 (0.36) | CYP2C9CYP2C19CCNCCDK8CCNT1 | |
| SCHEMBL23996985 | 0.80 | ESR1 (0.38) | CYP2C9CYP2C19CCNCCDK8CCNT1 | |
| SCHEMBL13106339 | 0.79 | CASP3 (0.48) | HTTLMNASMN1; SMN2CASP3CYP1A2 | |
| SCHEMBL1048915 | 0.78 | CASP3 (0.40) | HTTLMNASMN1; SMN2CASP3CYP1A2 | |
| SCHEMBL13106483 | 0.78 | CASP3 (0.40) | HTTLMNASMN1; SMN2CASP3CYP1A2 | |
| SCHEMBL19960782 | 0.77 | LRRK2 (0.36) | CCNCCDK8CCNT1CDK2CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119638640-A | Preparation method of 5-bromo-2-methyl-3-isopropyl-indazole | 杭州亦宁医药技术有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-113135858-A | Preparation method of 5-bromo-2-methyl-3-isopropyl-indazole | 倍而达药业（苏州）有限公司 | 2021-07-20 | — | — | CN | claimed |
| US-12378232-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2025-08-05 | — | — | US | disclosed |
| CN-119638640-A | Preparation method of 5-bromo-2-methyl-3-isopropyl-indazole | 杭州亦宁医药技术有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119638640-A | Preparation method of 5-bromo-2-methyl-3-isopropyl-indazole | 杭州亦宁医药技术有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119638640-A | Preparation method of 5-bromo-2-methyl-3-isopropyl-indazole | 杭州亦宁医药技术有限公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-3784664-B1 | 2-AMINO-PYRIDINE OR 2-AMINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-115232118-B | Protein kinase inhibitory activity small molecule and derivative, preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2024-07-19 | — | — | CN | disclosed |
| CN-118286225-A | 2-Amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | 辉瑞公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-112313219-B | 2-Amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | 辉瑞公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2024044757-A1 | AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-29 | — | — | WO | disclosed |
| US-9878994-B2 | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof | BETA PHARMA INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878994-B2 | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof | BETA PHARMA INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170210726-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210726-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210726-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| EP-3191469-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | Beta Pharma, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| CN-106687454-A | 2H-indazole derivatives as Cyclin Dependent Kinase (CDK) inhibitors and their medical use | 贝达医药公司 | 2017-05-17 | — | — | CN | disclosed |
| WO-2016014904-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016014904-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378232-B2 | Cyclin dependent kinase inhibitors | CCNY, CCNI, CCNK | HTT 3590/4885LMNA 1064/4885SMN1; SMN2 4086/4885 |
| US-20170210726-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | CDK4, CDK3, CDK6 | HTT 3573/4885LMNA 2087/4885SMN1; SMN2 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.